Laura Figulla is a biotech executive and founder CEO with extensive experience in life sciences, including strategic consulting, venture capital financing, and innovation strategy. Currently serving as a Strategic Advisor at NUCLIDIUM AG, they support the development of transformative copper-based radioligand therapeutics. Laura co-founded and led mbiomics GmbH, where they achieved a successful Series A financing of 13M EUR, and co-founded devie medical GmbH, focusing on groundbreaking drug delivery solutions for cardiovascular interventions. With a solid educational background that includes a Ph.D. in Health Economics from Universität Duisburg-Essen, Laura has also held significant roles at EY-Parthenon and coramaze technologies GmbH.
This person is not in the org chart
This person is not in any teams
This person is not in any offices